Journal of Chemotherapy最新文献

筛选
英文 中文
Mechanisms underlying dose-limiting toxicities of conventional chemotherapeutic agents. 传统化疗药物剂量限制性毒性的机制。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2024-12-01 Epub Date: 2024-01-05 DOI: 10.1080/1120009X.2023.2300217
Mohammad Amin Manavi, Mohammad Hosein Fathian Nasab, Razieh Mohammad Jafari, Ahmad Reza Dehpour
{"title":"Mechanisms underlying dose-limiting toxicities of conventional chemotherapeutic agents.","authors":"Mohammad Amin Manavi, Mohammad Hosein Fathian Nasab, Razieh Mohammad Jafari, Ahmad Reza Dehpour","doi":"10.1080/1120009X.2023.2300217","DOIUrl":"10.1080/1120009X.2023.2300217","url":null,"abstract":"<p><p>Dose-limiting toxicities (DLTs) are severe adverse effects that define the maximum tolerated dose of a cancer drug. In addition to the specific mechanisms of each drug, common contributing factors include inflammation, apoptosis, ion imbalances, and tissue-specific enzyme deficiencies. Among various DLTs are bleomycin-induced pulmonary fibrosis, doxorubicin-induced cardiomyopathy, cisplatin-induced nephrotoxicity, methotrexate-induced hepatotoxicity, vincristine-induced neurotoxicity, paclitaxel-induced peripheral neuropathy, and irinotecan, which elicits severe diarrhea. Currently, specific treatments beyond dose reduction are lacking for most toxicities. Further research on cellular and molecular pathways is imperative to improve their management. This review synthesizes preclinical and clinical data on the pharmacological mechanisms underlying DLTs and explores possible treatment approaches. A comprehensive perspective reveals knowledge gaps and emphasizes the need for future studies to develop more targeted strategies for mitigating these dose-dependent adverse effects. This could allow the safer administration of fully efficacious doses to maximize patient survival.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"623-653"},"PeriodicalIF":1.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antihyperlipidemic drug rosuvastatin suppressed tumor progression and potentiated chemosensitivity by downregulating CCNA2 in lung adenocarcinoma. 抗高血脂药物洛伐他汀通过下调CCNA2抑制肺腺癌的肿瘤进展并增强化疗敏感性
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2024-12-01 Epub Date: 2024-01-30 DOI: 10.1080/1120009X.2024.2308975
Xiang-Di Tan, Cui-Fang Luo, Si-Yu Liang
{"title":"Antihyperlipidemic drug rosuvastatin suppressed tumor progression and potentiated chemosensitivity by downregulating CCNA2 in lung adenocarcinoma.","authors":"Xiang-Di Tan, Cui-Fang Luo, Si-Yu Liang","doi":"10.1080/1120009X.2024.2308975","DOIUrl":"10.1080/1120009X.2024.2308975","url":null,"abstract":"<p><p>Rosuvastatin (RSV) is widely used to treat hyperlipidemia and hypercholesterolemia and is recommended for the primary and secondary prevention of cardiovascular diseases (CVD). In this study, we aimed to explore its action and mechanism in lung adenocarcinoma (LUAD) therapy. Lewis and CMT64 cell-based murine subcutaneous LUAD models were employed to explore the effects of RSV monotherapy combined with cisplatin and gemcitabine. Human lung fibroblasts and human LUAD cell lines were used to assess the effects of RSV on normal and LUAD cells. Bioinformatics and RNA interference were used to observe the contribution of cyclin A2 (CCNA2) knockdown to RSV inhibition and to improve chemosensitivity in LUAD. RSV significantly suppressed grafted tumor growth in a murine subcutaneous LUAD model and exhibited synergistic anti-tumor activity with cisplatin and gemcitabine. <i>In vitro</i> and <i>in vivo</i> experiments demonstrated that RSV impaired the proliferation and migration of cancer cells while showing little inhibition of normal lung cells. RNA interference and CCK8 detection preliminarily indicated that RSV inhibited tumor growth and enhanced the chemosensitivity to cisplatin and gemcitabine by downregulating CCNA2. RSV suppressed LUAD progression and enhanced chemosensitivity to cisplatin and gemcitabine by downregulating CCNA2, which should be prior consideration for the treatment of LUAD, especially for patients co-diagnosed with hyperlipidemia and hypercholesterolemia.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"662-674"},"PeriodicalIF":1.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blocking lncRNA HCG18 re-sensitizes Taxol resistant lung cancer cells to Taxol through modulating the miR-34a-5p/HDAC1 axis. 通过调节miR-34a-5p/HDAC1轴,阻断lncRNA HCG18可使对紫杉醇耐药的肺癌细胞对紫杉醇重新敏感。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2024-12-01 Epub Date: 2024-05-06 DOI: 10.1080/1120009X.2024.2308979
Fujun Zhang, Juan Wang, Haoyu Li, Xiaoyu Luo, Qiuyue Xu, Lin Liu, Yunmin Xu, Kai Yang, Zijie Liu, Rong Gong
{"title":"Blocking lncRNA HCG18 re-sensitizes Taxol resistant lung cancer cells to Taxol through modulating the miR-34a-5p/HDAC1 axis.","authors":"Fujun Zhang, Juan Wang, Haoyu Li, Xiaoyu Luo, Qiuyue Xu, Lin Liu, Yunmin Xu, Kai Yang, Zijie Liu, Rong Gong","doi":"10.1080/1120009X.2024.2308979","DOIUrl":"10.1080/1120009X.2024.2308979","url":null,"abstract":"<p><p>Lung cancer is one of the most frequently diagnosed cancers worldwide, associated with a poor survival rate. Taxol (Paclitaxel) is commonly used as a chemotherapeutic treatment for advanced lung cancers. While Taxol has improved clinical outcomes for lung cancer patients, a significant number of them develop resistance to Taxol, resulting in treatment failure. The role of the long noncoding RNA HCG18 in lung cancer and Taxol resistance has not yet been fully understood. To investigate this, we examined the expression of HCG18 and miR-34a-5p in lung tumors and normal lung tissues using qRT-PCR. We also assessed Taxol resistance through cell viability and apoptosis assays. Through the starBase online service, we analyzed the interactions between lncRNA and mRNA as well as miRNA and mRNA. We further validated the association between lncRNA and miRNA through luciferase and RNA pull-down assays. Our findings demonstrated that HCG18 was significantly upregulated in lung cancer tissues compared to normal lung tissues. Silencing HCG18 increased the sensitivity of lung cancer cells to Taxol. Additionally, our study established a Taxol-resistant cell line and observed a substantial upregulation of HCG18 in Taxol-resistant lung cancer cells. Bioinformatic analysis predicted that HCG18 could bind to miR-34a-5p, forming a competing endogenous RNA network, which was confirmed through luciferase assay. We found that miR-34a-5p was downregulated in lung cancer tissues and negatively correlated with Taxol resistance, as it directly bound to the 3'UTR region of HDAC1. Further results showed that inhibition of HCG18 significantly increased miR-34a-5p expression and sensitized lung cancer cells to Taxol. This sensitization could be reversed by inhibiting miR-34a-5p. Finally, we demonstrated in a xenograft mouse model that inhibition of HCG18 sensitized Taxol-resistant lung cancer cells to Taxol treatment by modulating the miR-34a-5p-HDAC1 axis. In conclusion, our in vitro and in vivo results uncover a novel molecular mechanism by which HCG18 promotes Taxol resistance through modulation of the miR-34a-5p/HDAC1 axis. These findings contribute to the diagnosis and treatment of chemo-resistant lung cancer.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"682-693"},"PeriodicalIF":1.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140866372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors associated with immune-related thyroid dysfunction induced by PD-1/PD-L1 inhibitors in cancer patients: an observational study. 癌症患者PD-1/PD-L1抑制剂诱发免疫相关甲状腺功能障碍的相关因素:一项观察性研究。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2024-12-01 Epub Date: 2024-01-19 DOI: 10.1080/1120009X.2024.2305065
Xiao-Chen Wei, Yuan-Yuan Guo, Yi Zhang, Yi-Shan Bu, Feng-Ying Zhang
{"title":"Factors associated with immune-related thyroid dysfunction induced by PD-1/PD-L1 inhibitors in cancer patients: an observational study.","authors":"Xiao-Chen Wei, Yuan-Yuan Guo, Yi Zhang, Yi-Shan Bu, Feng-Ying Zhang","doi":"10.1080/1120009X.2024.2305065","DOIUrl":"10.1080/1120009X.2024.2305065","url":null,"abstract":"<p><p>This study aimed to identify the potential factors associated with immune thyroid dysfunction caused by programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors in cancer patients. We conducted a retrospective study of thyroid immune-related adverse events (irAEs) in cancer patients treated with PD-1/PD-L1 inhibitors at Tianjin First Central Hospital from January 2020 to March 2023. Thyroid irAEs were characterized as hypothyroidism, hyperthyroidism and thyrotoxicosis followed by hypothyroidism. A total of 175 patients were screened in the study, of whom 48 patients (27%) developed thyroid irAEs (including 24 hypothyroidism, 11 hyperthyroidism and 13 thyrotoxicosis followed by hypothyroidism) following PD-1/PD-L1 inhibitors treatment. Multivariate logistic regression analysis showed that combination therapy with PD-1/PD-L1 inhibitors and tyrosine kinase inhibitors (lenvatinib/regorafenib) and high baseline anti-TPO level were associated with the development of thyroid irAEs caused by PD-1/PD-L1 inhibitors. The nomogram models showed good discriminant ability and could bring net benefits for more patients according to the decision curve analysis. However, the model needs to be further validated in other large cohorts.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"654-661"},"PeriodicalIF":1.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139491444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronic antibiotic suppressive therapy with dalbavancin: a case series. 使用达巴万星进行慢性抗生素抑制治疗:一个病例系列。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2024-12-01 Epub Date: 2024-05-07 DOI: 10.1080/1120009X.2024.2349442
Carlo Pallotto, Andrea Tommasi, Margherita Albagini, Giovanni Genga, Elisabetta Svizzeretto, Anna Gidari, Sara Tordi, Daniela Francisci
{"title":"Chronic antibiotic suppressive therapy with dalbavancin: a case series.","authors":"Carlo Pallotto, Andrea Tommasi, Margherita Albagini, Giovanni Genga, Elisabetta Svizzeretto, Anna Gidari, Sara Tordi, Daniela Francisci","doi":"10.1080/1120009X.2024.2349442","DOIUrl":"10.1080/1120009X.2024.2349442","url":null,"abstract":"<p><p>Dalbavancin is a relatively new long-acting anti-Gram positive antimicrobial approved for the treatment of acute bacterial skin and skin structures infections. An increasing number of observational studies and case series were published on its off-label uses. Great interest is emerging about complicated cases where antibiotic treatment cannot be discontinued, and a chronic suppressive therapy is needed. We described a case series of 6 patients treated or ongoing on treatment with dalbavancin as chronic suppressive therapy (CAST) administered with the following regimen: dalbavancin 1500 mg on day 1 and 8 and then every 4 weeks. CAST median duration was 27 weeks. Five out of 6 patients reached a good clinical control of the infection (one of them completely resolved) while in one case we observed a recurrence of the infection. No adverse events were detected. Larger studies are needed to better clarify dalbavancin off-label uses and the most appropriate dose regimen.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"717-721"},"PeriodicalIF":1.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140857181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intravesical sequential gemcitabine/docetaxel for non-muscle invasive bladder cancer: tips and tricks for better efficacy and tolerability. 膀胱内序贯使用吉西他滨/多西他赛治疗非肌层浸润性膀胱癌:提高疗效和耐受性的技巧和窍门。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2024-12-01 Epub Date: 2024-03-04 DOI: 10.1080/1120009X.2024.2325765
Mohamad Abou Chakra, Mohamad Moussa, Michael A O'Donnell
{"title":"Intravesical sequential gemcitabine/docetaxel for non-muscle invasive bladder cancer: tips and tricks for better efficacy and tolerability.","authors":"Mohamad Abou Chakra, Mohamad Moussa, Michael A O'Donnell","doi":"10.1080/1120009X.2024.2325765","DOIUrl":"10.1080/1120009X.2024.2325765","url":null,"abstract":"","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"694-697"},"PeriodicalIF":1.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140028188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ribociclib-induced autoimmune-like hepatitis: a case report. 核糖素诱导自身免疫样肝炎1例。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2024-11-28 DOI: 10.1080/1120009X.2024.2433368
Gozde Kavgaci, Taha Koray Sahin, Cenk Sokmensuer, Hatice Yasemin Balaban, Sercan Aksoy
{"title":"Ribociclib-induced autoimmune-like hepatitis: a case report.","authors":"Gozde Kavgaci, Taha Koray Sahin, Cenk Sokmensuer, Hatice Yasemin Balaban, Sercan Aksoy","doi":"10.1080/1120009X.2024.2433368","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2433368","url":null,"abstract":"<p><p>Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer represents the most prevalent subtype of breast cancer. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, in combination with endocrine therapy (ET), have shown substantial benefits in improving progression-free survival and, for ribociclib, an overall survival advantage. Despite clinical benefits, ribociclib is associated with elevated liver enzymes and severe liver dysfunction. We present a 44-year-old Caucasian woman with HR-positive, HER2-negative metastatic breast cancer who developed drug-induced autoimmune-like hepatitis (DI-ALH) after ribociclib therapy. Initially treated for early-stage disease with surgery, chemotherapy, radiotherapy, and ET, she progressed to metastatic disease and received ribociclib, letrozole, and goserelin, achieving a partial response. Treatment was complicated by grade 3 hepatotoxicity, confirmed as DI-ALH by liver biopsy. Managed with prednisolone and azathioprine, ribociclib was reintroduced at a reduced dose and later escalated to full dose. This case report highlights the importance of a multidisciplinary approach to balance oncologic efficacy with hepatologic safety.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":1.9,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142751006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey. 治疗局部晚期或转移性放射性碘难治性分化型甲状腺癌的索拉非尼与化疗:来自土耳其的真实数据。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2024-11-26 DOI: 10.1080/1120009X.2024.2430845
Nargiz Majidova, Shahla Aghamaliyeva, Murat Guliyev, Gülhan Dinc, Arif Akyıldız, Erkan Ozcan, Fatma Akdağ Kahvecıoglu, Hasan Çağrı Yıldırım, Nadiye Sever, Ali Kaan Guren, Erkam Kocaaslan, Pınar Erel, Yesim Agyol, Abdussamet Celebi, Rukiye Arıkan, Selver Isık, Ibrahim Vedat Bayoglu, Nebi Serkan Demirci, Ömer Dizdar, Ilhan Hacıbekiroğlu, Osman Kostek, Murat Sarı
{"title":"Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey.","authors":"Nargiz Majidova, Shahla Aghamaliyeva, Murat Guliyev, Gülhan Dinc, Arif Akyıldız, Erkan Ozcan, Fatma Akdağ Kahvecıoglu, Hasan Çağrı Yıldırım, Nadiye Sever, Ali Kaan Guren, Erkam Kocaaslan, Pınar Erel, Yesim Agyol, Abdussamet Celebi, Rukiye Arıkan, Selver Isık, Ibrahim Vedat Bayoglu, Nebi Serkan Demirci, Ömer Dizdar, Ilhan Hacıbekiroğlu, Osman Kostek, Murat Sarı","doi":"10.1080/1120009X.2024.2430845","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2430845","url":null,"abstract":"<p><p>Managing locally advanced, or metastatic radioactive iodine-refractory differentiated thyroid cancers (RAIR-DTC) poses substantial challenges, with few available treatment options. The aim of this study was to evaluate clinical outcomes of patients receiving sorafenib as first line treatment. In addition, prognostic markers affecting progression-free survival (PFS) were identified. This retrospective, 6 centers study included 62 patients with locally advanced or RAIR-DTC treated 2008-2023. The median PFS was 16.5 months. The presence of liver metastases was strongly associated with a lower PFS (3.1 months (<i>p</i> < 0.001)). The use of sorafenib as initial treatment resulted longer PFS compared to chemotherapy, with a median of 25.5 vs 4.7 months respectively (<i>p</i> = 0.01). Increased neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with worse outcomes (<i>p</i> = 0.01; <i>p</i> = 0.009, respectively). In conclusion, sorafenib has demonstrated significant PFS benefits when used as first-line treatment. It has been shown that the presence of liver metastases and higher levels of NLR and PLR are associated with a more unfavorable prognosis.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":1.9,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcriptional factor KLF9 overcomes 5-fluorouracil resistance in breast cancer via PTEN-dependent regulation of aerobic glycolysis. 转录因子KLF9通过PTEN依赖性调节有氧糖酵解克服乳腺癌的5-氟尿嘧啶耐药性
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2024-11-03 DOI: 10.1080/1120009X.2024.2421701
Liang Xu, Jing Sun, Junlan Guo, Shengnan Guo, Jiangli Li, Yijun Tang, Xiaohui Liu
{"title":"Transcriptional factor KLF9 overcomes 5-fluorouracil resistance in breast cancer via PTEN-dependent regulation of aerobic glycolysis.","authors":"Liang Xu, Jing Sun, Junlan Guo, Shengnan Guo, Jiangli Li, Yijun Tang, Xiaohui Liu","doi":"10.1080/1120009X.2024.2421701","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2421701","url":null,"abstract":"<p><p>The emergence of resistance to 5-Fluorouracil (5-FU) is a staple in breast cancer chemotherapy. This paper delves into the role of PTEN in breast cancer resistance to 5-FU and examines the underlying molecular pathways. PTEN expression was detected in bioinformatics databases and upstream transcription factors (TFs) were identified. PTEN mRNA and protein levels, aerobic glycolysis proteins, lactate production, glucose consumption, and cell viability were measured. Binding interactions were confirmed, and cell proliferation assessed. In breast cancer cells, PTEN expression was downregulated. PTEN overexpression counteracted 5-FU resistance through the suppression of aerobic glycolysis. KLF9, as a TF upstream of PTEN, enhanced the levels of PTEN. In conclusion, the TF KLF9 inhibits the aerobic glycolysis level of breast cancer cells by up-regulating PTEN expression, thereby reducing their resistance to 5-FU. The discovery of this mechanism provides a new theoretical basis for the treatment of breast cancer.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":1.9,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
METTL3-mediated m6A modification promotes chemoresistance of intrahepatic cholangiocarcinoma by up-regulating NRF2 to inhibit ferroptosis in cisplatin-resistant cells. METTL3 介导的 m6A 修饰通过上调 NRF2 来抑制顺铂耐药细胞的铁凋亡,从而促进肝内胆管癌的化疗耐药性。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2024-11-01 DOI: 10.1080/1120009X.2024.2421700
Xiaoping Zheng, Huiying Li, Jian Lin, Ping Li, Xuexi Yang, Zhumei Luo, Li Jin
{"title":"METTL3-mediated m6A modification promotes chemoresistance of intrahepatic cholangiocarcinoma by up-regulating NRF2 to inhibit ferroptosis in cisplatin-resistant cells.","authors":"Xiaoping Zheng, Huiying Li, Jian Lin, Ping Li, Xuexi Yang, Zhumei Luo, Li Jin","doi":"10.1080/1120009X.2024.2421700","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2421700","url":null,"abstract":"<p><p>This study explores the relationship between m6A modification and ferroptosis in intrahepatic cholangiocarcinoma (ICC) and its impact on cisplatin resistance. We established cisplatin-resistant cells. CCK-8 and Transwell assays were conducted to evaluate the effects of METTL3 on drug resistance, migration, and invasion. RT-qPCR and Western blotting were used to measure target gene expression and the effects of overexpression and suppression. RIP, luciferase reporter assay, and other experiments were utilized to investigate the interaction between METTL3 and NRF2. Additionally, rescue experiments were performed to confirm the role of the METTL3/NRF2 axis in tumor drug resistance. METTL3 was found to be highly expressed in cisplatin-resistant cells, enhancing m6A modification levels, stabilizing NRF2 mRNA, and increasing NRF2 protein expression to inhibit ferroptosis. These findings indicate that the METTL3/NRF2 axis inhibits ferroptosis in cisplatin-resistant cells, thereby promoting chemotherapy resistance in ICC. This provides a potential direction for future research and treatment of ICC.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":1.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信